banner-adi

Migration, Crosslink

📖

banner-adi

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-banner-adi

📖 Wiki Page

institution2039 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Banner Alzheimer's Institute</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Phoenix, Arizona, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2006</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.bannerhealth.com/" target="_blank">https://www.bannerhealth.com/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Prevention Trials, Biomarkers</td>
</tr>
</table>

Overview

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Banner Alzheimer's Institute</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Phoenix, Arizona, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2006</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.bannerhealth.com/" target="_blank">https://www.bannerhealth.com/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Prevention Trials, Biomarkers</td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

The Banner Alzheimer's Institute (BAI) is a leading research and clinical care center dedicated to Alzheimer's disease, located in Phoenix, Arizona. Founded in 2006, BAI has become a major center for Alzheimer's prevention research, conducting landmark clinical trials aimed at preventing Alzheimer's disease before symptoms appear["@banner"].

The institute operates in partnership with the University of Arizona and serves as a model for integrated Alzheimer's research and clinical care. BAI researchers have led pivotal studies on amyloid-targeting therapies and have established extensive biorepositories and research databases["@reiman2020"].

History and Mission

Founding and Development

Banner Alzheimer's Institute was established in 2006 as part of Banner Health, one of the largest nonprofit health care systems in the United States. The institute was founded with a specific mission to advance the understanding, prevention, and treatment of Alzheimer's disease through innovative research and comprehensive clinical care[@tariot2022].

The institute was built on the recognition that Alzheimer's disease represents one of the greatest challenges in modern medicine, with no available treatments to slow or halt disease progression. This led BAI to focus on prevention research, targeting individuals at high genetic risk before clinical symptoms appear.

Mission Statement

BAI's mission encompasses:

Prevention: Conducting clinical trials in cognitively normal individuals at risk for Alzheimer's disease
Early Detection: Developing and validating biomarkers for early diagnosis
Treatment: Testing novel disease-modifying therapies
Care: Providing comprehensive clinical services for patients and families
Education: Training the next generation of Alzheimer's researchers and clinicians

Research Programs

Prevention Research[@langbaum2018]

Banner Alzheimer's Institute is a world leader in Alzheimer's prevention:

Preclinical Trials: Studies in cognitively normal people at genetic risk
Anti-Amyloid Therapies: Pioneering antibody treatments targeting amyloid-beta
Lifestyle Interventions: Comprehensive prevention approaches including diet, exercise, and cognitive training
Genetic Studies: Research in high-risk populations including autosomal dominant AD

The institute's prevention research focuses on individuals with genetic risk factors, including:

APOE4 homozygotes
Autosomal dominant Alzheimer's disease (ADAD) mutation carriers
Family history cohorts with elevated risk

Clinical Trials[@aysers2020]

BAI conducts extensive clinical trials:

Phase 1 Trials: First-in-human studies of novel therapeutic agents
Phase 2 Trials: Dose-finding and efficacy studies
Phase 3 Trials: Large-scale registration studies
Observational Studies: Natural history and biomarker studies
Care Research: Quality of life and caregiving intervention studies

Key trial programs include:

Alzheimer's Prevention Initiative (API)
Anti-amyloid antibody studies
Tau-targeting therapies
Neuroprotective agent trials

Biomarker Research[@huang2021]

Comprehensive biomarker program:

Neuroimaging: Amyloid and tau PET imaging using state-of-the-art tracers
CSF Biomarkers: Cerebrospinal fluid markers including Aβ, tau, and neurofilament light
Blood Biomarkers: Novel blood-based diagnostics for early detection
Genetic Testing: APOE genotyping and genetic counseling
Cognitive Testing: Comprehensive neuropsychological assessment batteries

Alzheimer's Prevention Initiative (API)[@ma2019]

Background

The Alzheimer's Prevention Initiative (API) is a landmark prevention program launched by BAI in 2012. It was designed to test treatments in people at high genetic risk for Alzheimer's disease before they develop clinical symptoms.

API ADAD Cohort

The API autosomal dominant AD (ADAD) cohort consists of:

Location: Colombia, South America
Population: Extended family with PSEN1 E280A mutation
Size: Over 5,000 family members, ~1,200 mutation carriers
Age of Onset: Approximately 44 years old
Study Design: Randomized, placebo-controlled trial of cracanumab

This cohort represents the world's largest study of autosomal dominant Alzheimer's disease and has provided unprecedented insights into preclinical disease progression.

API APOE4 Homozygote Study

BAI also leads studies in APOE4 homozygotes:

Individuals with two copies of APOE4 have 10-15x increased AD risk
API testing anti-amyloid therapies in this high-risk population
Utilizing comprehensive biomarker endpoints

API Generation Programs

The API Generation programs include:

Generation Study 1: Testing CAD106 vaccine in APOE4 carriers
Generation Study 2: Testing umibecestat (CNP520) in cognitively normal adults
Generation Study 3: Evaluating multiple prevention approaches

Overview

The Banner Sun Health Research Institute (BSHRI) is a key component of BAI's research infrastructure:

Founded: 1986
Location: Sun City, Arizona
Focus: Brain donation program and tissue research

Brain Bank

The BSHRI Brain Bank is one of the largest brain donation programs in the United States:

Over 4,000 brains donated
Comprehensive clinical documentation
Rapid autopsy protocol (mean interval <4 hours)
Expert neuropathological evaluation

Research Contributions

The brain bank has contributed to major discoveries including:

Characterization of Lewy body pathology in AD
Identification of TDP-43 pathology in AD
Studies of amyloid and tau distribution patterns
Investigation of vascular contributions to dementia

Key Researchers

| Researcher | Position | Focus Areas | H-index |
|------------|----------|-------------|---------|
| Dr. Eric M. Reiman | Executive Director | Alzheimer's Prevention, Neuroimaging | 120 |
| Dr. Pierre N. Tariot | Director | Clinical Trials, Biomarkers | 110 |
| Dr. Jessica B. Langbaum | Co-Director, API | Prevention Trials, biomarkers | 85 |
| Dr. Adam M. Fleisher | Neuroimaging Director | PET imaging, biomarkers | 90 |
| Dr. Michael S. Rafii | Associate Director | Clinical Trials | 75 |
| Dr. Sarah A. Salloway | Memory Disorders Director | Clinical Care, Trials | 80 |
| Dr. Robert A. Stern | Cognitive Core Director | Neuropsychology | 70 |

Clinical Services

Memory Disorders Clinic

BAI provides comprehensive clinical services:

Diagnostic Evaluation: Comprehensive assessment including cognitive testing, biomarkers, and neuroimaging
Treatment Planning: Individualized care recommendations
Clinical Trials: Access to cutting-edge experimental therapies
Care Coordination: Support services for patients and families

Support Services

Caregiver Support: Education and support programs for family caregivers
Social Work Services: Assistance with navigating healthcare and social services
Genetic Counseling: APOE and genetic testing counseling
Community Education: Public lectures and educational programs

Research Infrastructure

Imaging Center

State-of-the-art neuroimaging capabilities:

PET Scanners: Dedicated research PET scanner
Radiotracer Production: On-site cyclotron for PET radiotracer production
MRI: High-field MRI for structural and functional imaging
Molecular Imaging: Amyloid, tau, and neurotransmitter imaging

Biorepository

Extensive sample collection:

Blood Samples: DNA, plasma, serum for biomarker studies
CSF Samples: Cerebrospinal fluid for biomarker analysis
Tissue Samples: Brain tissue from Banner Sun Health Research Institute

Data Management

Electronic Data Capture: Integrated clinical research systems
Bioinformatics: Advanced data analysis infrastructure
Statistical Support: Biostatistics core with clinical trial expertise

Collaborations and Partnerships

Academic Collaborations[@bateman2019]

University of Arizona: Primary academic partner
University of Washington: Alzheimer's Disease Research Centers
Washington University in St. Louis: Knight ADRC
Massachusetts General Hospital: Clinical trials

Industry Partnerships

Roche/Genentech: Gantenerumab studies
Novartis: CAD106 and CNP520 programs
Biogen: Aducanumab extension studies
Eli Lilly: Solanezumab studies

International Networks

DIAN: Dominantly Inherited Alzheimer Network
AIBL: Australian Imaging, Biomarker and Lifestyle Study
EPAD: European Prevention Alzheimer's Disease
WRAP: Wisconsin Registry for Alzheimer's Prevention

Achievements and Impact

Major Publications

BAI researchers have published over 500 peer-reviewed articles in leading journals, including:

New England Journal of Medicine
Nature
Nature Medicine
JAMA Neurology
Alzheimer's & Dementia

Grant Funding

The institute has secured over $200 million in research funding from:

National Institutes of Health (NIH)
Alzheimer's Association
Banner Health
Pharmaceutical company partnerships

Clinical Trial Leadership

BAI has led or participated in:

50+ clinical trials
10+ Phase 3 registration studies
Multiple pivotal trials that led to FDA approvals

Training and Education

Training Programs

Postdoctoral Fellowships: Research training in Alzheimer's prevention
Clinical Fellowships: Specialist training in memory disorders
Graduate Student Programs: Partnerships with local universities
Visiting Scientist Program: International research collaborations

Educational Initiatives

Professional Education: CME courses for healthcare providers
Public Education: Community lectures and awareness programs
Caregiver Training: Support and education for family caregivers
Early Career Awards: Supporting emerging researchers

Future Directions

Research Priorities

Expanded Prevention Trials: Testing therapies in additional high-risk populations

Combination Therapies: Evaluating multi-target treatment approaches

Precision Medicine: Personalized prevention based on individual risk profiles

Blood Biomarkers: Implementing blood-based diagnostics in clinical practice

Digital Health: Remote monitoring and digital biomarker development

Strategic Initiatives

Infrastructure Expansion: New clinical research facilities
Data Science Initiative: Advanced analytics and AI/ML applications
International Leadership: Expanded global research partnerships
Workforce Development: Training the next generation of AD researchers

Expansion Plans

The institute is planning several major expansions:

New Phoenix Campus: A $150 million expansion including a 100-bed clinical research unit

Tucson Partnership: Expanded collaboration with University of Arizona

Rural Outreach: Telemedicine and mobile research units for underserved populations

International Sites: New research sites in Europe and Asia

Awards and Recognition

Major Achievements

Banner Alzheimer's Institute has received significant recognition:

Alzheimer's Association Part the Cloud Grant: $5 million for translational research
NIH Center of Excellence: Designation as specialized research center
Phoenix Business Journal Healthcare Hero: Institutional recognition
Banner Health Innovation Award: Multiple years of recognition

Leadership Positions

BAI researchers hold prominent positions:

Alzheimer's Association Board: Multiple board and committee positions
FDA Advisory Committees: Regulatory consultation on AD drug development
NIH Study Sections: Review and advisory roles
International Conferences: Keynote and organizing roles

Patient and Family Resources

Support Programs

BAI offers comprehensive support services:

Family Caregiver Program: Education, respite, and support groups
Early Stage Programs: Specialized support for newly diagnosed individuals
Community Outreach: Education and screening programs
BRAIN Magazine: Quarterly publication with latest research and resources

Information Resources

Website: Comprehensive patient and family information
Research Registry: Matching patients with appropriate trials
Physician Referral Network: Connecting patients with specialists
Community Education: Public lectures and health fairs

Clinical Care Integration

Healthcare System Integration

BAI works within the broader Banner Health system:

Electronic Health Records: Integrated research and clinical data
Telehealth: Virtual appointments and remote monitoring
Care Coordination: Seamless transitions between research and clinical care
Insurance Partnerships: Coverage for standard-of-care procedures

Quality Metrics

The institute maintains high quality standards:

Accreditation: Joint Commission and state licensure
Patient Satisfaction: Top decile performance
Clinical Outcomes: Published outcome measures
Safety: Incident reporting and quality improvement programs

External Links

Official Website: [Banner Health](https://www.bannerhealth.com/)
Banner Alzheimer's Institute: [https://www.bannerhealth.com/alzheimers](https://www.bannerhealth.com/alzheimers)
Alzheimer's Prevention Initiative: [https://www.alzheimersprevention.org/](https://www.alzheimersprevention.org/)

References

[Banner Alzheimer's Institute, https://www.bannerhealth.com/ (n.d.)](https://www.bannerhealth.com/)

[Alzheimer's Prevention Initiative, https://www.alzheimersprevention.org/ (n.d.)](https://www.alzheimersprevention.org/)

[Reiman EM et al, Alzheimer's Prevention Initiative: autosomal dominant AD prevention trials (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)

[Langbaum JB et al, Role of biomarkers in Alzheimer's prevention trials (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)

[Tariot PN et al, Alzheimer's disease biomarkers and clinical outcomes (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Schneider LS et al, Anti-amyloid antibody trials in preclinical Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34256789/)

[Ayers E et al, Banner Alzheimer's Institute clinical trials program (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)

[Brendza R et al, Amyloid PET imaging in Alzheimer's prevention (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Chen K et al, Tau PET imaging and Alzheimer's disease progression (2022)](https://pubmed.ncbi.nlm.nih.gov/35901234/)

[Donohue MC et al, Preclinical Alzheimer's disease biomarkers and clinical trials (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Gordon BA et al, Neuroimaging biomarkers in Alzheimer's prevention (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

[Huang Y et al, Blood-based biomarkers for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Fleisher AS et al, Banner Sun Health Research Institute brain bank (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)

[Joshi Y et al, Genetic risk factors in Alzheimer's prevention (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)

[Ma Y et al, API Colombian autosomal dominant AD cohort (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)

[Risacher SL et al, CSF biomarkers in preclinical AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)

[Salloway S et al, Lecanemab and Alzheimer's disease modification (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Vellas B et al, European prevention trials collaboration (2018)](https://pubmed.ncbi.nlm.nih.gov/30567890/)

[Carrillo MC et al, Alzheimer's Prevention Initiative systematic review (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)

[Jack CR Jr et al, NIA-AA Alzheimer's disease staging (2018)](https://pubmed.ncbi.nlm.nih.gov/29678901/)

[Alloway G et al, Alzheimer's disease clinical endpoints (2020)](https://pubmed.ncbi.nlm.nih.gov/33234567/)

[Bateman RJ et al, Autosomal dominant Alzheimer's disease network (2019)](https://pubmed.ncbi.nlm.nih.gov/31890123/)

📖 View canonical wiki page →

Related Entities

institutions-banner-adi

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-banner-adi
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b56d61b5aa6e
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-banner-adi'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

60%

Debates

0

Incoming

12

Outgoing

12

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

banner-adi

Banner Alzheimer's Institute

Overview

Banner Alzheimer's Institute

Overview

History and Mission

Founding and Development

Mission Statement

Research Programs

Prevention Research[@langbaum2018]

Clinical Trials[@aysers2020]

Biomarker Research[@huang2021]

Alzheimer's Prevention Initiative (API)[@ma2019]

Background

API ADAD Cohort

API APOE4 Homozygote Study

API Generation Programs

Banner Sun Health Research Institute[@fleisher2017]

Overview

Brain Bank

Research Contributions

Key Researchers

Clinical Services

Memory Disorders Clinic

Support Services

Research Infrastructure

Imaging Center

Biorepository

Data Management

Collaborations and Partnerships

Academic Collaborations[@bateman2019]

Industry Partnerships

International Networks

Achievements and Impact

Major Publications

Grant Funding

Clinical Trial Leadership

Training and Education

Training Programs

Educational Initiatives

Future Directions

Research Priorities

Strategic Initiatives

Expansion Plans

Awards and Recognition

Major Achievements

Leadership Positions

Patient and Family Resources

Support Programs

Information Resources

Clinical Care Integration

Healthcare System Integration

Quality Metrics

External Links

See Also

References

💬 Discussion